Regardless of the ideology selected, the academic perspective elected, or the corporate edifices that are being erected to fulfill the promise of genomic therapies, the central challenge for personalized medicine will always be to more exactly identify.
We now know that there are 3 critical junctures in the inhibition of cancer’s cascade; the Inception, the Intervention and the Inhibition. Therefore, DNA-SEQ provides oncologists a methodology to navigate the complex cycle of inhibiting a cancer and thereby restoring regulated cell growth, preserving both the quality of life and the promise of a future for their patients. The process is as follows.
The Inception: Map the Triggers
The Intervention: Out Compete the Trigger
A specific drug was developed that could locate the ABL “activating terminals” and effectively bind to them which cuts off the signaling supplies that cancer needs to grow. No activating signal - no growth. Rapid patient recovery.
The Inhibition: Match the Resistance Mutation and Cease the Signal
The Patient resistance produces a new mutation in ABL in an attempt to establish a new signal terminal. A specific drug was developed that locates, binds with, and shuts down the last source of signaling for the cancer. Patients return to a state of controlled cell growth. Patients enjoy a long-term recovery.
Some medical breakthroughs have been stumbled upon, some require rigorous targeted precision. With cancer, close just isn’t good enough. Precision is the measure of efficacy.
“In cancer treatment and drug discovery, efficacy is everything.”
Janusz M. Sowadski, Chairman & CEO of the DNA-SEQ Alliance